DUO-O: A randomized phase Ill trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients Meeting Abstract
| Authors: | Harter, P.; Bidziński, M.; Colombo, N.; Floquet, A.; Pérez, M. J. R.; Kim, J. W.; Lheureux, S.; Marth, C.; Nyvang, G. B.; Okamoto, A.; Reuss, A.; Scambia, G.; Trillsch, F.; Ali Vardar, M.; Van Nieuwenhuysen, E.; Lichfield, J.; Rugman, P.; Twumasi-Ankrah, P.; Aghajanian, C. |
| Abstract Title: | DUO-O: A randomized phase Ill trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 338s |
| Language: | English |
| ACCESSION: | WOS:000487345803385 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.TPS5598 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS5598 -- Source: Wos |
